Microgravity Exposes a Thrombosis Question Space Medicine Has Not Yet Answered
Spaceflight alters human physiology in ways that matter to clot biology. Venous return slows, endothelial signaling changes, and multiple ground-based analogs point toward a more prothrombotic state, yet no eligible studies have directly tested anticoagulation for the prevention or treatment of venous thromboembolism in microgravity-exposed individuals. The review searched 13 biomedical and aerospace databases and found zero studies meeting predefined PICOS criteria. That absence leaves clinicians and flight medicine teams with a familiar but uncomfortable problem: risk is biologically plausible, but direct therapeutic evidence is missing.
No Direct Anticoagulation Data Emerged From the Search
The review followed PRISMA methods and searched MEDLINE, Embase, Scopus, Web of Science, the Cochrane Library, CINAHL, NASA Technical Reports Server, ESA archives, ClinicalTrials.gov, NASA Life Sciences Data Archive, ISS Publications Archive, the DLR database, and the NASA SS Research Database. Despite the breadth of that search, no study qualified for inclusion. Neither astronauts nor individuals in microgravity analogs had been studied in a way that could answer the practical question at the center of this topic: whether pharmacologic thromboprophylaxis or treatment can be used safely and effectively when gravity is removed from the equation.
The negative result is clinically meaningful. A null evidence base in a niche environment can be more consequential than a small positive trial in routine care, because mission planning depends on decisions made before the first clot occurs. In space, the threshold for intervention must account not only for thrombosis prevention but also for bleeding risk, drug stability, dosing logistics, and limited rescue capability.
Physiology Points Toward Venous Stasis and Hypercoagulability
To contextualize the lack of direct anticoagulation trials, the review synthesized physiologic and terrestrial evidence relevant to thrombotic risk. Across microgravity and ground-based analog studies, several convergent changes appeared: venous stasis, endothelial dysfunction, increased fibrinogen synthesis, altered platelet function, and hypercoagulability. Each of those shifts maps onto a recognized element of Virchow’s triad. Reduced venous return promotes stasis, altered endothelial behavior weakens the vessel wall’s antithrombotic properties, and changes in coagulation proteins and platelet behavior tilt the balance toward clot formation.
This is not a theoretical concern abstracted from a laboratory model. Human physiology in microgravity redistributes fluid centrally, reshapes vascular loading, and changes the mechanical forces that normally help regulate endothelial tone. When that mechanical input disappears, the vascular system appears to move toward a state that could support clot formation, even if clinically apparent events remain uncommon.
Why VTE May Be Rare in Spaceflight Yet Still Clinically Relevant
The review concluded that VTE appears rare in spaceflight. Rare does not mean irrelevant. A low event rate may reflect true low incidence, the limited number of exposed individuals, under-detection, short mission durations, selection of exceptionally healthy crew members, or the fact that some thrombotic events could resolve or go unrecognized without routine surveillance. In this setting, absence of observed harm is not the same as proof of safety for withholding prophylaxis, just as absence of direct events is not proof that no one is at risk.
That uncertainty matters most in extended missions, when cumulative exposure to microgravity, dehydration, altered activity, and constrained medical support could change the risk equation. A short orbital flight and a prolonged interplanetary mission are not interchangeable clinical environments. The review’s evidence synthesis points toward the need for risk stratification tools that account for mission duration, individual predisposition, and environmental constraints rather than borrowing terrestrial assumptions wholesale.
Anticoagulant Use in Space Needs Evidence, Not Extrapolation Alone
The review’s central finding is the complete lack of direct data on anticoagulant safety and efficacy in microgravity. That gap matters because every anticoagulant class carries tradeoffs. Bleeding complications can be difficult to manage far from definitive care, and the pharmacologic behavior of drugs may differ under altered fluid distribution, motion, nutrition, and physiologic stress. Even if a medication performs predictably on Earth, spaceflight can alter the conditions that determine whether the same dose remains appropriate.
A bedside problem emerges immediately from that uncertainty. If a crew member develops suspected thrombosis during a mission, clinicians need a protocol that addresses diagnosis, treatment selection, and evacuation thresholds without relying on evidence that does not exist. The review therefore points toward a dual need: better preflight risk assessment and mission-specific contingency planning for anticoagulation.
Research Priorities for Flight Medicine and Thrombosis Prevention
The review calls for studies that evaluate anticoagulant safety and efficacy in microgravity, refine VTE risk assessment tools, and develop evidence-based protocols to protect astronaut health. Those priorities are not interchangeable. Risk tools help identify who might need intensified surveillance or preemptive measures. Safety studies clarify whether anticoagulants can be used without unacceptable bleeding risk. Protocol development then translates that information into operational practice for space agencies and flight surgeons.
Ground-based analogs can contribute useful mechanistic data, but analogs are not substitutes for actual microgravity exposure. The vascular system responds to gravity in ways that are difficult to reproduce fully on Earth. For that reason, future work will need to bridge bench physiology, operational medicine, and real-world mission constraints rather than treating them as separate domains.
The immediate takeaway is narrow and concrete: space medicine currently lacks direct evidence to guide anticoagulation in microgravity, even as physiologic signals point toward a plausible prothrombotic state. Until that gap closes, decisions about thromboprophylaxis will continue to depend on extrapolation, individualized judgment, and protocols built on incomplete data rather than on validated spaceflight trials.